Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. - Wikidata - awgldk - TriplyDB

Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.

Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.

http://www.wikidata.org/entity/Q35057364

about

Mesothelioma treatment: Are we on target? A review Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma.Novel systemic therapy against malignant pleural mesothelioma.Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials.Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).Molecular pathogenesis of malignant mesothelioma.Receptor tyrosine kinase inhibitors: Are they real tumor killers?Searching for targets for the systemic therapy of mesothelioma.An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.Advances in treatment of mesothelioma.Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?Gremlin-1 is a key regulator of the invasive cell phenotype in mesothelioma.A review of bevacizumab in the treatment of malignant pleural mesothelioma.Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer.Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma.Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review.

P2860

Q26800042-FFBD4EE2-7DB6-4127-AFF0-AF528593C4AC Q28395597-1DFFA8D4-E796-496B-898F-BB616BF0C19C Q33563281-A8B420AD-3D49-49CC-BE2C-0454FD8DCE07 Q33812537-BBDE8387-FA8C-4035-BA2A-1F94ABEE0238 Q33890499-DE809440-B19A-4CBD-B16B-331AAC775EE8 Q34622818-A62A71B5-2FEA-4E4F-8224-C51CAB68677D Q35042668-D0B7D2D1-27B4-438A-A6A1-13A4441212F2 Q35118673-B4D946AC-B0C6-4A47-9851-43EFC811AEB4 Q37090808-566551DD-D933-469D-8FBC-5A318C9FB674 Q37111141-83E8041C-E08E-4A67-B7C8-D77B345C19C6 Q38107102-A971E108-74A5-46AF-A24D-C33344F3A017 Q38365290-0E9DF852-156E-4FF3-A80F-8012EB998D1E Q38365768-7804775B-8235-4DAC-86E5-586C0A4A4B51 Q38525073-7D4DEC95-E5BC-41F1-B5C9-43311FACC30E Q38800916-9F5B2C15-B5B7-4F56-9E7A-723D0999E5D9 Q39127820-1D40B1B2-975B-48B0-B6FA-A036C689E78F Q47099675-61126794-2B62-4668-882A-A5AAA83F4763 Q47685374-3929EB59-5254-43D0-978D-3CD566A79256 Q48774492-4E8A8396-0692-4F0B-8C0D-4DAE30D6EB26 Q52642770-8560921B-9D7C-4FB4-8AD1-25031D5303DC Q55398166-99374102-3BCF-4F7E-9D93-4EF826A1C9C9

P2860

Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.

http://www.wikidata.org/entity/Q35057364

description

2012 nî lūn-bûn

@nan

2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Cediranib in patients with mal ...... f Chicago Phase II Consortium.

@ast

Cediranib in patients with mal ...... f Chicago Phase II Consortium.

@en

type

label

Cediranib in patients with mal ...... f Chicago Phase II Consortium.

@ast

Cediranib in patients with mal ...... f Chicago Phase II Consortium.

@en

prefLabel

Cediranib in patients with mal ...... f Chicago Phase II Consortium.

@ast

Cediranib in patients with mal ...... f Chicago Phase II Consortium.

@en

P1433

Q35057364-30959757-06E9-4675-B0E8-B61708A8F65A

P1476

Q35057364-980D1CF1-D819-4427-B06F-5D715675E5D0

P2093

Q35057364-1F306A96-9CFF-40A6-9C5E-8495EC5B904A

Q35057364-3AC5591F-21B5-42E3-8DF5-16E464C000AB

Q35057364-63F141B4-5B91-49C5-9B49-18D8D7295070

Q35057364-6FFF99A4-84C5-4483-A847-332508DFF33D

Q35057364-84742E2A-B9E2-43B6-BEED-242225E89D24

Q35057364-A96FD039-A203-43BA-98D6-C509ED05C148

Q35057364-A9C67446-2241-4AEC-A9E9-E628F75B3759

Q35057364-B661A27D-24F2-40AE-B8D2-5AB129297BFF

Q35057364-BFB04E97-7B7B-46F9-8A47-14F7B1D9B970

Q35057364-C7BEC320-1758-456C-87EB-A92EE203EDD6

P2860

Q35057364-1D2D1460-51DE-46E6-8438-79255B591DA3

Q35057364-284CCE47-0543-40FC-BFD6-16D8AB827DCB

Q35057364-35C0F394-4E0B-4173-B988-B28588D2A53E

Q35057364-36107ED1-C11C-443B-B534-458D27F11815

Q35057364-36D92EB9-968B-4CD5-A413-5CA0B1E4D6D2

Q35057364-3C4FDCB0-6BCE-4C82-8D92-702A00DA5F19

Q35057364-52690521-DB29-4788-AA06-15BA2D025026

Q35057364-56094424-BD62-4FC0-AAC7-07E3E2A800FB

Q35057364-61D80FEB-3F81-4550-8AB7-61E0FB9C5AC8

Q35057364-68CCC758-22F0-4519-BCF6-994CC72BDC02

P304

Q35057364-20B240BC-439B-46DA-9FDC-EE08CCD785CF

P31

Q35057364-7B7904EF-9626-4C23-AA21-C1F86FB6F3BB

P356

Q35057364-F21E36D8-5102-42CF-9AF8-5AA87566ADB4

P433

Q35057364-06A4310D-E7C4-476A-9596-071295198A5E

P478

Q35057364-23FF731A-50A8-422A-BE52-B15A17E126FF

P50

Q35057364-4BE1CAD3-8FFA-4E90-9938-A71855719415

Q35057364-C15793A0-33B1-4E82-98ED-AF5B3EDF0EB3

P577

Q35057364-4FD636E1-4AA8-43EC-AA52-F53B69D5595E

P698

Q35057364-0236D2B1-B566-41E7-9CB5-D94B4DE4AEF0

P921

Q35057364-A97B930B-7F4D-4AA7-94CA-5D20880ECFCD

P932

Q35057364-CD5097F8-9847-435A-8C21-124B26D3A583

P356

J.LUNGCAN.2012.06.011

P1433

P1476

Cediranib in patients with mal ...... f Chicago Phase II Consortium.

@en

P2093

Barbara J Gitlitz

http://www.w3.org/2001/XMLSchema#string

Edem Agamah

http://www.w3.org/2001/XMLSchema#string

Hedy L Kindler

http://www.w3.org/2001/XMLSchema#string

Marianna Koczywas

http://www.w3.org/2001/XMLSchema#string

Mark D Vincent

http://www.w3.org/2001/XMLSchema#string

Natasha Leighl

http://www.w3.org/2001/XMLSchema#string

Nicholas P Campbell

http://www.w3.org/2001/XMLSchema#string

Rangesh Kunnavakkam

http://www.w3.org/2001/XMLSchema#string

Sachdev P Thomas

http://www.w3.org/2001/XMLSchema#string

Walter M Stadler

http://www.w3.org/2001/XMLSchema#string

P2860

Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma

Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509

Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).

Vascular endothelial growth factor (VEGF) signaling in tumor progression.

P304

76-80

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.LUNGCAN.2012.06.011

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

78

http://www.w3.org/2001/XMLSchema#string

P50

David R Gandara

Everett E Vokes

P577

2012-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22831987

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

4319647

http://www.w3.org/2001/XMLSchema#string